CA-AIRSPACE-TECH
10.12.2020 14:02:12 CET | Business Wire | Press release
Airspace Technologies, Inc. (Airspace), the company revolutionizing air cargo and time-critical logistics, has opened its first European office, with the launch of Airspace B.V. From the headquarters, located at Schiphol-Rijk, the Netherlands, which opened in June this year, Airspace will be expanding its team across the Netherlands, France, Germany, and the U.K., in line with its rapid growth plans to fulfill customer demand.
Airspace’s technology is transforming and modernizing the logistics industry. Their proprietary software uses machine learning to identify the fastest and lowest risk path out of millions of possibilities. The technology proactively ensures that any potential delays are avoided and guarantees the customer real-time, end-to-end visibility. While officials anticipate significant problems at the borders due to Brexit, Airspace’s technology will greatly reduce the impact of the logistics issues for the customer and allow vital products and services to still be delivered on time.
The new European operation will be managed by Marcel Andriessen, who has successfully led logistics companies specializing in worldwide time-critical services over the last 20 years. Andriessen was the Managing Director at time:matters for 10 years and was responsible for the success of their European business and the expansion into the U.S. Andriessen will lead the Airspace BV organization as Managing Director.
“I am looking forward to getting back into time-critical logistics and to bring Airspace’s leading-edge technology to the European market. Customers here have not experienced the speed and transparency that Airspace offers, and I welcome the opportunity to show them how much better time-critical logistics can be,” said Andriessen.
The company’s expansion is in response to the demand from global customers who want to further leverage the Airspace technology for their European operations. Industry-leading customers including Quest Diagnostics, Varian Medical, and Allegiant Air Corporation, already rely on Airspace’s proprietary logistics technology and robust delivery network to deliver their mission-critical shipments as fast as possible throughout North America and Europe. They rely on the technology platform Airspace has developed to provide real-time, door-to-door transparency throughout the entire shipment process. This is most important for life-saving industries, such as the medical profession, which depend on rapid deliveries.
“The time-critical market is full of difficult problems. Customers too often have a poor experience because the industry is trying to solve these problems using antiquated practices. Shippers across Europe need a modern platform that can provide the level of transparency and error prevention that these critical shipments deserve,” said Nick Bulcao, Co-Founder & CEO of Airspace Technologies, Inc.
About Airspace Technologies, Inc.
Based in Carlsbad, Calif., Airspace Technologies, Inc. was founded in 2015 and has grown to be the most trusted leader in time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints within a shipment, Airspace surfaces more information than any other provider, increasing the velocity and transparency of the supply chain.
To learn more about Airspace, please visit www.airspacetechnologies.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005537/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
